Meta-analysis of 35 RCTs found semaglutide produced the largest BMI and metabolic improvements among pediatric obesity pharmacotherapies, while metformin showed modest benefits and all GLP-1RAs had manageable GI side effects.
Very large BMIz reduction with semaglutideSemaglutide produced the largest effect on BMI z-score among all pediatric obesity medications in 35-trial meta-analysis
What the researchers found
Semaglutide produced the largest BMI z-score reduction (very large effect), largest triglyceride reduction, and meaningful quality-of-life improvement among pediatric obesity pharmacotherapies in a meta-analysis of 35 RCTs.
Why it matters
Childhood obesity is a global crisis with limited pharmacological options. This meta-analysis establishes the evidence hierarchy among available drugs and positions semaglutide as the most effective option — informing clinical guidelines and treatment decisions.
The numbers in context
RCTs through November 2022; under-18 participants; assessed PROMs, cardiometabolic risk factors, anthropometry, and adverse events.
How the study worked
Systematic review and meta-analysis of 35 RCTs in children <18 years. GRADE certainty of evidence assessed. Effects presented relative to minimal important differences. Agents: metformin (26 RCTs), GLP-1RAs (7 RCTs), orlistat (2 RCTs).
Who was studied
Children and adolescents under 18 with obesity
What this study cannot tell us
Limited number of GLP-1RA trials (especially semaglutide — only 1 RCT). Short intervention durations (3-24 months). Few studies assessed patient-reported outcomes. Long-term effectiveness and safety of GLP-1RAs in children not yet established. Heterogeneity across trials.
How to read the evidence
Moderate to strong evidence — systematic review with GRADE methodology covering 35 RCTs, but semaglutide evidence based on only 1 trial. Metformin evidence is most robust (26 RCTs).
When this study was published
Published in 2024 with evidence through November 2022. Captures the emerging pediatric GLP-1RA evidence base.
The bigger picture
This meta-analysis will likely influence clinical practice guidelines for pediatric obesity pharmacotherapy. The clear hierarchy (semaglutide > liraglutide/exenatide > metformin > orlistat) provides evidence-based guidance, though long-term safety data for GLP-1RAs in children remains needed.
Questions still open
- Will additional semaglutide pediatric trials confirm these promising results?
- What is the optimal age to start pharmacotherapy for childhood obesity?
- How long should children remain on these medications — indefinitely or for defined courses?
Common questions
What is the most effective weight loss medication for children?
Are weight loss drugs safe for children?
Read the original research
Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline.
Pediatric obesity, 19(11), e13169
Citation
Wahi, Gita; St-Pierre, Julie; Johnston, Bradley C; Fitzpatrick-Lewis, Donna; Usman, Ali; Sherifali, Diana; Merdad, Roah; Esmaeilinezhad, Zahra; Birken, Catherine S; Hamilton, Jill; Henderson, Mélanie; Moore, Sarah A; Ball, Geoff D C; Morrison, Katherine M. (2024). Effectiveness of pharmacological interventions for managing obesity in children and adolescents: A systematic review and meta-analysis framed using minimal important difference estimates based on GRADE guidance to inform a clinical practice guideline.. Pediatric obesity, 19(11), e13169. https://doi.org/10.1111/ijpo.13169